Boston-based ORIG3N, Inc. is a biotechnology company with the world’s largest uniformly consented cell repository that can be used to understand rare diseases, develop a treatment, and personalized medicine. In December, 2015, the company successfully completed its series A round, raising $12.5 million. DEFTA Partners, along with the company’s existing investors such as Harris & Harris Group, Inc., LabCorp, MGC Venture Partners, and KTB KORUS Fund, participated in the round.
The press release can be found here.
- On January 13, 2016